• LAST PRICE
    3.9100
  • TODAY'S CHANGE (%)
    Trending Up0.1000 (2.6247%)
  • Bid / Lots
    3.7000/ 2
  • Ask / Lots
    4.0500/ 2
  • Open / Previous Close
    3.8800 / 3.8100
  • Day Range
    Low 3.8000
    High 3.9700
  • 52 Week Range
    Low 2.9000
    High 10.5000
  • Volume
    25,947
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.81
TimeVolumeATHE
09:42 ET5103.88
09:46 ET1003.87
09:53 ET2003.85
10:04 ET6003.83
10:11 ET10003.85
10:33 ET2003.87
10:38 ET5783.88
10:44 ET1003.9132
10:56 ET54013.88
11:14 ET2003.8801
11:36 ET1003.88
11:39 ET2003.925
11:45 ET1003.905
12:01 ET2503.9
12:26 ET1013.905
12:44 ET1003.88
01:31 ET5003.91
01:42 ET2003.94
02:45 ET1003.94
02:50 ET11003.91
02:54 ET2003.91
02:57 ET18003.92
02:59 ET10003.9
03:14 ET1003.9
03:15 ET1003.9053
03:17 ET6003.93
03:21 ET70383.9699
03:24 ET4503.91
03:26 ET2003.935
03:33 ET2903.935
03:53 ET1003.97
03:55 ET3003.91
03:57 ET2003.91
04:00 ET3003.91
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesATHE
Alterity Therapeutics Ltd
17.2M
-0.2x
---
United StatesLIXT
Lixte Biotechnology Holdings Inc
12.2M
-1.6x
---
United StatesBUDZ
Weed Inc
12.3M
-10.5x
---
United StatesKZIA
Kazia Therapeutics Ltd
17.5M
-0.8x
---
United StatesBZYR
Burzynski Research Institute Inc
12.5M
-14.4x
---
United StatesDFFN
Diffusion Pharmaceuticals Inc
12.6M
-0.8x
---
As of 2023-01-29

Company Information

Alterity Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes. ATH434 has been granted Orphan Drug designation for the treatment of Multiple System Atrophy.

Contact Information

Headquarters
L 3 460 Bourke StMELBOURNE, VIC, Australia 3000
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Geoffrey Kempler
Chief Executive Officer
David Stamler
Chief Financial Officer
Kathryn Andrews
Company Secretary
Phillip Hains
Non-Executive Director
Lawrence Gozlan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$17.2M
Revenue (TTM)
$1.8K
Shares Outstanding
4.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.21
EPS
$-22.75
Book Value
$62.80
P/E Ratio
-0.2x
Price/Sales (TTM)
9,680.7
Price/Cash Flow (TTM)
---
Operating Margin
-739,582.40%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.